H.L. Ormond & Company’s Outlook Therapeutics OTLK Stock Holding History

H.L. Ormond & Company’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500	Closed	-$13K	–	108
2021 Q4	$13K	Buy	+500	New	+$17.8K	0.02%	104

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

H.L. Ormond & Company's OTLK Position: Q1 2022 in Review

H.L. Ormond & Company sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 500 shares — an estimated $13K sold.

H.L. Ormond & Company first reported a position in OTLK in Q4 2021 and held it in 1 quarter. The position peaked at $13K in Q4 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

H.L. Ormond & Company reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
H.L. Ormond & Company sold 500 Outlook Therapeutics shares in Q1 2022, an estimated $13K.
H.L. Ormond & Company first reported a position in Outlook Therapeutics in Q4 2021 and held it in 1 quarter.
H.L. Ormond & Company's Outlook Therapeutics position peaked at $13K in Q4 2021.
73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on H.L. Ormond & Company's 13F filing for Q1 2022, filed 11 May 2022.